Introduction: To estimate the value of interventions in multiple sclerosis (MS) -where lifetime costs and outcomes cannot be observed -outcome data have to be combined with costs. This requires that cost data be regularly updated.
Introduction
Hungary was one of the first countries in Central Eastern Europe to set up a formal health technology assessment (HTA) process, and guidelines for conducting health economic analyses were first released in 2002 by the Ministry of Health. 1 Cost-effectiveness studies and budget impact analyses have been integrated into the decision-making processes, and all new drugs (since 2004) and medical devices (since 2007) are evaluated by the HTA agency. As a consequence, the number of health economic studies has increased, but studies in multiple sclerosis (MS) are limited. A European project on the cost of brain diseases included prevalence and cost estimates for MS in Hungary based on extrapolation from available European data. 2 Another project studying the access to disease-modifying treatments (DMTs) for MS in Europe estimated costs and treatment access using similar methodology. 3 A small cross-sectional survey in two hospital-based neurology centres in 2009 and a small cost study performed with the patient association in 2010 were the first to provide specific Hungarian data on the burden of MS. 4, 5 The availability of DMTs has led to changes in patient management and a focus on earlier and better diagnosis and adjustments in the diagnostic criteria themselves. 6, 7 One of the consequences in this regard is that the recorded prevalence of the disease is quite different from that estimated two or three decades ago. 8, 9 In Hungary, crude prevalence in Baranya County was reported to be 37/100,000 in 1983, while representative population surveys in Csongrád County revealed a crude prevalence of 62/100,000 in 1999 and 89.8/100,000 in 2013. 10, 11 With diagnosis possible already after one clinically isolated event, 7 one must also expect a different distribution of the type of MS and severity of the disease compared to 10 years ago: a larger proportion of patients with relapsingremitting disease and thus of patients in the early stages of the disease, with less disability.
It is therefore important to update the information on the burden of MS, and the study presented here is part of a European-wide effort in 16 countries to investigate the burden of MS, endorsed by the European Platform of MS Societies (EMSP) and carried out with the support of national MS societies. 12 It uses a similar methodology as the last European survey in 2005. 13
Materials and methods
The detailed methodology for the European survey is published separately. 14 We therefore only provide a short summary of the general methods and issues specific to Hungary.
Data
The study aimed to estimate the costs of all healthcare and other resource utilisation related to MS: hospitalisation, rehabilitation, consultations, diagnostic procedures and tests, medication, community care, family support and production losses (sick leave, early retirement, invalidity). In addition, information on major symptoms such as fatigue and cognitive difficulties (using visual analogue scale (VAS)), health-related quality of life (HRQoL) as well as self-assessed disability using descriptions based on the Expanded Disability Status Scale (EDSS) were collected.
Data were collected with a standard questionnaire, at a single point in time, for a retrospective period of time. The latter was varied depending on the question to minimise recall bias: 1 month for use of drugs, community services and informal care; 3 months for hospitalisation, consultations, tests, sick leave and relapses; 12 months for major investments. Resource utilisation is reported for these time periods, while cost calculations are annualised.
Disease information such as the type of MS, disability (EDSS), HRQoL, utility (EuroQol five dimensions (EQ-5D) 15 ), symptoms (fatigue, cognitive difficulties) and the effect of MS on work related to the current day or week. For comparability across countries in the survey, 16 utilities were estimated in all countries with the original value set developed in the United Kingdom. 17 Also, in Hungary, no specific local value set has been developed yet.
The handling of missing data for the cost calculation is explained in more detail in the article describing the methods of this survey. 14 For resource use, we present actual answers without any imputation for missing responses. Also, no imputations are made for missing information on disease type and status, symptoms and HRQoL.
Costs
Costs are calculated from the societal perspective, including all costs regardless of who ultimately is responsible for them. Patient co-payments and patients' out-of-pocket expenses are thus included.
The cost of a relapse is calculated as the difference in quarterly costs between patients with or without a relapse and an EDSS score of 0-6, with the hypothesis that relapses were seldom longer than 3 months and were less frequent at higher EDSS levels. Patients who were unsure whether they had a relapse or not were excluded from this calculation. Costs that are unlikely to be affected within 3 months (invalidity, early retirement and DMT treatment) were excluded.
Unit costs for the individual resources were taken from public sources and summarised in the description of the study methods. 14 The results are reported in Hungarian Forint (HUF 2015; €1 = 309.75 HUF average exchange rate 2015).
Patients
The objective was to include a sample where all levels of disease severity (defined by EDSS) were represented in sufficient numbers to permit analysis, rather than a prevalence sample. This allows highlighting how costs and HRQoL change as the disease progresses and provides the necessary data for costeffectiveness analysis of treatments that are expected to change the course of the disease. The mean results may thus not be representative and should neither be extrapolated directly to national costs nor be compared directly to the results in earlier studies. We therefore report the results by disease severity groups only (mild disability EDSS 0-3, moderate disability EDSS 4-6.5, severe disability EDSS 7-9).
Data collection
It is generally difficult to include a fully representative patient population in anonymous surveys as participation will depend heavily on the methods used for the survey: collecting data in MS centres tends to overestimate the number of patients with early but severe disease and on treatment with DMTs; 18 collecting data from members of patient organisations may lead to the opposite. Internet surveys will bias towards younger patients with better education, while postal surveys may bias towards older patients.
The Hungarian patients were exclusively recruited through the Hungarian MS Society (Magyar Sclerosis Multiplex Társaság). The data were collected during the winter 2015/2016, after approval by the ethics commission (Scientific and Research Committee of the Hungarian Medical Research Council -Egészségügyi Tudományos Tanács, Tudományos és Kutatásetikai Bizottság; registration no. 11736-1/2015/EKU). Informed consent was obtained from all participants included in the study. The MS society distributed the survey to 4000 members through their usual distribution channels (e-mail, postal surveys), and the call for participation was advertised in various media.
Results
A total of 521 evaluable responses were received (310 on-line and 211 on paper). Patients from all regions were represented according to the population, with a slightly higher participation in Budapest and in 5 of the 19 counties (Fejér, Jász-Nagykun-Szolnok, Komárom-Esztergom, Nógrád and Vas). Table 1 provides details on demographics, employment and disease.
Demographics and employment
The age of respondents in Hungarian patients ranged from 20 to 88 years (mean 46.9 years, median 46.0 years, standard deviation (SD) 12.0 years); women represented 78%; 83% lived with their family and nine patients (1.7%) were in a nursing home at the time of the survey.
In this sample, 6% of patients had basic education, 60% a secondary or a professional degree and 34% a university degree. This reflects a higher educational level than in the Hungarian general population in the same age groups in 2011 (30-49 years: 15%, 61% and 23%; 50-64 years: 24%, 59% and 16%). 19 This is not surprising, considering the relatively young age of the participants and a majority of on-line answers. However, it is also possible that patients with better education are better informed and more willing to get in contact with patient organisations and participate in surveys.
The majority of patients in the sample were of working age (defined as average effective retirement age, 59.6 years for women and 60.9 years for men 20 ): 443 patients (85%). Of these, 211 patients (47%) were employed or self-employed. Eight patients above retirement age also worked, bringing this group to 219 patients (or 42% of the full sample), with a mean age of 41.9 years (SD 9.7 years). This compares to an activity rate of 64.8% in the population between 15 and 64 years in 2015 (57.8% for women and 70.3% for men). 19 A large group worked part-time (41%), and of these, 19% did so because of MS. In the general population, 6% of all employed (8% of women) work part-time. 19 The average weekly working hours in the sample were 41.5 hours for full-time workers and 22 hours for part-time employees. Sick leave during the past 3 months was reported by 39 patients (18%), with a mean duration of 12.5 days.
Employment decreased rapidly with advancing disease, as shown in Figure 1 . Of non-employed patients of working age, 44% indicated MS as the reason. Within the full sample, 40% indicated having left the workforce due to MS.
Most employed patients felt that MS affected their productivity at work (82%) and only 12% indicated that they had no problems, while 6% had not answered the question. The severity of the effect covered the entire VAS range from 0 to 10, with a mean of 3.6 (SD 2.5; Figure 2 ). Fatigue was considered the most bothersome symptom (62%), followed by mobility (29%), difficulties thinking (28%), pain (28%) and low mood (26%).
Disease information
Disease information is summarised in Table 1 . The mean EDSS in the sample was 3.9 (SD 2.5). The number of patients at each EDSS level exceeded 40, except at EDSS 0 and 9 with only 36 and 9 patients, respectively. For our analysis, the mild group (EDSS 0-3) represented 49% of the sample, the moderate group (EDSS 4-6.5) 33% and the severe group (EDSS 7-9) 17%; EDSS data were missing for three patients.
The proportion of patients with relapsing-remitting multiple sclerosis (RRMS) was 55%, with secondary progressive multiple sclerosis (SPMS) at 18% and with primary progressive multiple sclerosis (PPMS) at 21% (missing 7%). This latter proportion is higher than what is generally expected. 8 A recent study in Hungary (Csongrád County) found only 6% of patients with PPMS while 14% had SPMS, 69% had RRMS and 11% had clinically isolated syndrome (CIS). 11 We therefore did not include this information in our analysis and focused on EDSS levels instead.
DMTs were used by 58% of patients, with usage lower in the high EDSS levels, as expected (Table 1) . Among users, 32% were on their first DMT treatment. First-generation DMTs were used by 59% of patients ( Table 2) .
Relapses in the preceding 3 months were reported by 129 patients (25%) and happened at all stages of the disease, 253 patients (49%) indicated no relapse, 136 patients (26%) were unsure whether they had a relapse or not and 3 patients did not answer. For these two latter groups, we assumed that the answer was no. Thus, the mean relapse rate over a 3-month period was estimated at 0.4 (SD 0.8), which in view of the DMT treatment rate can be considered high. However, considering the large proportion of patients reporting to be unsure, one must accept a certain degree of uncertainty in these answers. Also, corticosteroids were only used by 33 patients in the sample, which might point towards a lower number of relapses.
Symptoms and HRQoL
Fatigue and cognitive difficulties were an issue for a majority of patients, and both were related to disease severity ( Figure 2 ). Fatigue was present in 94% of patients who answered the VAS (N = 509). The mean score was 5.6 (SD 2.7) for the sample, 4.7 for patients with mild diseases, 6.2 for patients in the moderate group and 7.2 for patients in the severe group. Cognitive difficulties were recognised by 66% of patients. The mean VAS score in this group was 4.4 (SD 2.1) overall, 3.7 in the mild, 4.9 in the moderate and 5.4 in the severe group.
For the full study sample (assigning 0 to the group with no problems), the mean score was 3.0 (SD 2.7) and 2.4, 3.7 and 3.2 in the three groups, respectively.
Among the five domains of HRQoL included in the EQ-5D, only self-care did not represent problems for a majority of patients with mild disease. Both the severity and the type of domain affected changed with advancing disease (Figure 3 ).
Utility
Utility decreased with increasing EDSS (Figure 4 ). The mean utility in this specific sample was 0.522 (SD 0.3), estimated with the UK tariff. 17 Figure 1 . Proportion of patients below retirement age employed or self-employed; 443 patients (85%) were below retirement age, and of these, 47% were employed or self-employed.
EDSS: Expanded Disability Status Scale. 
Resource utilisation
Resource utilisation is shown in Investments in equipment and devices to aid patients' mobility were made during the past 12 months for or by 192 patients (37%), most often for walking aids and modifications to the car or the house. Community and social services were used by 23% of patients, most frequently home help and personal assistance. Help from family was used by 53% of patients, on average 16.3 days per month and 5.9 hours per day. Both community services and informal care were related to disease severity ( Figure 5 ).
Costs
The total mean annual costs per patient for patients with mild, moderate and severe disease and by EDSS score are presented in Figure 6 and Table 4 .
The average cost of a relapse for patients with an EDSS 0-6 was estimated at 240,500HUF. All types of costs increased during a relapse, with informal care representing 35% of the additional costs, and hospital care and community services 25% each (Figure 7 ).
Discussion
The aim of this study was to estimate the current economic and health burden of MS in Hungary and to assess the impact of fatigue and cognitive symptoms on daily living. The study recruited patients at all levels of disability and represents the first large burden of illness study of MS in Hungary. Overall, the results are in agreement with the literature, showing that the costs of MS increase with advancing EDSS level, while utilities decrease. 21, 22 Our results also confirm the significant burden that MS represents for patients and their family and the negative impact on HRQoL as the disease progresses. Already in mild disease, around 50%-60% of patients had at least moderate problems with mobility, had problems to perform everyday activities, suffered from moderate pain and were emotionally affected. In moderate disease, nearly all patients experienced these problems. A remarkable worsening in mobility, self-care and usual activities and thus dependence on others was observed in severe disease stage and was reflected by the intense use of informal care and an almost total loss of work capacity.
Fatigue was present in almost all patients and at all disease stages, and a large proportion of patients felt that they had cognitive difficulties. This has also been shown in other studies. Fatigue was present in 62% of patients with RRMS in a recent study by Fricska-Nagy et al. 23 Sandi et al. 24 compared 65 patients with RRMS with age-, gender-and education-matched healthy controls and found that fatigue can have a negative impact on cognition which, in turn, could worsen HRQoL.
The rate of relapses reported in Hungary was the highest among the countries participating in this We did not include the self-reported disease type in our analysis, as it appeared that patients found it difficult to assess. This was the case in all 16 countries of the survey, and in particular PPMS appeared systematically overestimated. The reasons are not apparent from our study, but the results might indicate that the disease type is not always clearly communicated to patients, or in the case of older patients, diagnosis was only made late when patients already had progressive disease. 25 However, for our analysis of costs and HRQoL, this is not an issue, as these are primarily driven by EDSS, not the type of disease.
The mean annual costs per patient increased from 3.4 to 6.2 million HUF (11,000-20,000EUR) between mild and severe disease. Healthcare costs decreased with advancing disease, while services, informal care and production losses increased. DMT costs were a significant proportion of costs in mild and moderate disease. However, for the interpretation of our results, it is important to consider that list prices were used for the calculation of drug costs. Biologic drugs have been financed via the itemised payment system since 2012 and are purchased via public procurement tenders. The actual purchase prices are kept confidential, but we must assume that they are lower than list prices. Thus, our results may overestimate drug costs to some extent.
The two studies of the cost of MS in Hungary were performed in 2009 and 2010 and involved small samples of patients. 4, 5 Compared to our results, the proportion of patients treated with newer DMTs is, as expected, much smaller. Hospitalisation was similarly high, and an explanation for this may be the financing system in Hungary that encourages hospital admission for treatment (e.g. infusions) that could be provided in outpatient care as well. Total cost estimates cannot be compared directly, due to both the difference in the samples and the time lag and the difference in the availability of DMTs. Although costs were lower in the two earlier studies, trends were similar.
In conclusion, information on the HRQoL and cost of illness in Hungary is limited. This study provides the first comprehensive assessment of the burden of MS in Hungary. The results can help clinicians in the management of MS patients and serve as inputs for health economic analyses to support reimbursement decisions. and statistical support; to Markas Gedminas (Medscinet) for construction of the on-line platform; to Barbara Rosengren for language editing and to Cara Harley for formatting.
